CryptoHeartBeat

Researchers at the University of Pennsylvania have developed an innovative antiviral chewing gum that neutralizes over 95% of certain viruses in saliva, offering a simple, plant-based way to potentially curb transmission through everyday chewing. Led by Henry Daniell at Penn's School of Dental Medicine, the team created a clinical-grade gum incorporating a natural antiviral trap protein called FRIL (Flt3 Receptor Interacting Lectin), derived from lablab beans (Lablab purpureus, also known as hyacinth beans). This protein binds to complex-type N-glycans on the envelopes of various viruses, entrapping them and preventing infection or spread. Building on earlier work with a different gum containing plant-produced ACE2 (which reduced SARS-CoV-2 in saliva samples by >95% and is now in clinical trials), the latest formulation targets a broader range of pathogens. Lab tests showed that just 40 mg of the bean-based gum (from a 2-gram tablet) achieved more than 95% reduction in viral loads for influenza A strains (H1N1 and H3N2) and herpes simplex viruses (HSV-1 and HSV-2). The gum releases FRIL effectively during chewing, acting as a molecular decoy right at the site of viral replication in the mouth—key for limiting spread via talking, coughing, sneezing, or close contact. The product is engineered for real-world practicality: it remains stable and fully functional at room temperature for over 790 days, meets FDA clinical-grade standards, and uses safe, natural ingredients. While the ACE2 version (targeting COVID-19) has advanced to human trials, this FRIL-based gum shows strong promise for seasonal threats like flu and herpes, and researchers are even exploring lablab bean powder against bird flu (H5N1) in animal feed. If proven effective in upcoming clinical studies, this could become a low-cost, non-invasive tool for high-risk settings—schools, dental offices, public transport, or during outbreaks—helping reduce oral viral transmission without drugs or vaccines. [Daniell et al., "Debulking influenza and herpes simplex virus strains by a wide-spectrum anti-viral protein formulated in clinical grade chewing gum," Molecular Therapy (2024). DOI: 10.1016/j.ymthe.2024.12.008]